4 potentially lucrative biotechs for the patient investor

Financial journalist and commentator on 3AW and Sky Business
Print This Post A A A

The variety of approaches and focuses among Australia’s range of life science companies is amazing. The research and intellectual property that comes out of Australian universities and companies is very highly regarded around the world, and for good reason. Here are four very different examples of Australian biotechs pushing the knowledge envelope, with potentially very lucrative outcomes. Biotech is not a sector for faint-hearted investors – there are many possible pitfalls, and some of the companies below have experienced them – but the rewards for the patient investor can outweigh the fluctuations along the way.

1. Neuren (NEU, $1.24) 
Market capitalisation: $127 million
One-year total return: –60.6%
Three-year total return: –16.1% a year
Five-year total return: –7.6% a year

Neuren Pharmaceuticals (NEU) has two main drug candidates in development, Trofinetide and NNZ-2591. Trofinetide is targeting the rare neurological conditions Rett Syndrome and Fragile X Syndrome and is also being investigated as a treatment for traumatic brain injury.

Also from this edition